Pfizer (PFE.US) Tukysa receives U.S. approval for first-line breast cancer treatment

智通财经2026/10/08 02:41

Show original

According to Zhitong Finance APP, Pfizer (PFE.US) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor Tukysa (tucatinib) as part of a combination therapy for first-line maintenance treatment of a certain type of breast cancer.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Earnings Preview | Rocket Lab (RKLB.US) faces ongoing profitability pressure despite strong revenue growth as Neutron launch delays gradually fade

智通财经•2026/11/09 08:01

Google (GOOGL.US) warns that Australia's new cybersecurity regulations could cut off minors' access to Gmail

智通财经•2026/11/09 07:30

AI transformation dividends strengthen profit growth logic! SAP (SAP.US) upgraded to "Overweight" by JPMorgan, target price raised to 275 euros

JPMorgan has upgraded its rating on SAP from "Neutral" to "Overweight" in its latest report, raising the target price from 175 euros in December 2027 to 275 euros in December 2028, implying an upside potential of approximately 30%.

智通财经•2026/11/09 07:02

AI transformation dividends strengthen the logic of profit growth! SAP (SAP.US) receives an upgrade to “Overweight” from JPMorgan, with target price raised to 275 euros

智通财经•2026/11/09 07:01